$SGRY

Surgery Partners To Sell 2 Idaho Hospitals To Intermountain For $795 Mln, Backs FY View; Shares Jump

Surgery Partners (SGRY) said it signed agreements to sell its interests in Mountain View Hospital and Idaho Falls Community Hospital in Idaho to Intermountain Health for about $795 million. The hospitals were valued around $1.15 billion. Surgery Partners reaffirmed its FY2026 revenue of $3.35B to $3.45B and adjusted EBITDA of at least $530M excluding the deal. Shares rose to about $16.51.

Original reporting
Published Jul 24, 2026, 3:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 24, 2026, 3:38 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Surgery Partners To Sell 2 Idaho Hospitals To Intermountain For $795 Mln, Backs FY View; Shares Jump — source image
Decision brief

The 30-second read

$SGRYBullishMed
01

Why it matters

The transaction provides a large cash consideration ($795M) while management reiterates 2026 revenue ($3.35B to $3.45B) and adjusted EBITDA (at least $530M) excluding deal impact, which can influence investor expectations for earnings durability and capital deployment.

02

Market read

A disclosed hospital sale with quantified consideration and reaffirmed 2026 guidance is a concrete catalyst for valuation and deal-close expectations, ahead of the next earnings print.

03

What to watch

Key deal terms and closing conditions are not provided; any regulatory or operational contingencies could delay proceeds and extend uncertainty into the Aug 10 earnings window.

Relevance 8/10Novelty 8/10Timing: ahead of Q2 results on Aug 10, with deal close expected in coming months

Background

Surgery Partners operates short-stay surgical facilities and is now exiting ownership interests in two Idaho hospitals via a sale to Intermountain Health.

Company-level read

Ticker impact

$SGRYBullishMedium confidence
Context

Surgery Partners signed agreements to sell Mountain View Hospital and Idaho Falls Community Hospital to Intermountain for about $795M and reaffirmed 2026 guidance excluding the deal.

Expected impact

Shares may remain supported while investors price deal proceeds and the reaffirmed outlook, with volatility around deal-close timing and any closing conditions.

Evidence & confidence

The article discloses a specific transaction value ($795M consideration) plus quantified 2026 guidance ranges excluding the deal, which are direct inputs to earnings power and capital allocation expectations.

Market effects

Signals continued consolidation and asset rotation in short-stay surgical facility ownership, potentially affecting deal comps and buyer appetite.

Could shift local hospital ownership and referral dynamics in Idaho, though the article does not quantify operational impacts.

Limited beyond US healthcare facility M&A read-through; no cross-border elements mentioned.

Counterpoint

The guidance is reaffirmed only excluding the deal, so investors may be over-weighting near-term earnings impact without clarity on post-close integration or any one-time effects.

Key entities

  • Surgery Partners, Inc.

    Short-stay surgical facility operator signing agreements to sell two Idaho hospitals to Intermountain Health for about $795M and reaffirming 2026 outlook excluding the deal.

  • Intermountain Health

    Health system acquiring ownership interests in Mountain View Hospital and Idaho Falls Community Hospital.

  • Mountain View Hospital

    Idaho hospital included in the sale; physician ownership remains unchanged.

  • Idaho Falls Community Hospital

    Idaho hospital included in the sale.

Related articles

$SGRYMed

Why Is Surgery Partners Stock Gaining Friday? - Surgery Partners (NASDAQ:SGRY)

Surgery Partners (SGRY) said it will sell its ownership interests in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health for about $795 million, valuing the facilities at roughly $1.15 billion, subject to physician partner approval. The company reaffirmed fiscal 2026 revenue of $3.35 billion to $3.45 billion and adjusted EBITDA of at least $530 million.

$SGRYMedAI 8/10

Surgery Partners jumps on $1.15B hospital sale deal By Investing.com

Surgery Partners (NASDAQ:SGRY) rose 5.8% after agreeing to sell two Idaho Falls hospitals to Intermountain Health for about $1.15B. Surgery Partners expects about $795M for its ownership interests, with cash proceeds subject to purchase price adjustments. The deal needs approvals and regulatory steps and is expected to close in coming months. 2026 outlook was reaffirmed excluding the deal.

$SGRYMed

Why Surgery Partners (SGRY) Stock Is Trading Up Today

Surgery Partners (SGRY) shares rose about 2.7% in the morning to around $17.15 after Cantor Fitzgerald reiterated an “Overweight” rating and set an $18.00 price target. Cantor cited some softness in Q2 ambulatory surgery center and outpatient nursing data, but kept a positive view. Other analysts expect profitability this year.

MedAI 9/10

Nielsen To Buy DoubleVerify For $2.15 Billion In Ad Measurement Deal

Nielsen agreed to buy DoubleVerify in an all-cash deal valued at about $2.15 billion, paying $13.60 per share, a 30% premium to the stock’s 60-day VWAP as of Aug. 5. The boards approved; closing is expected by Q1 2027, subject to approvals. Pro forma revenue is expected to exceed $4 billion.

$RTXMedAI 8/10

RTX wins up to $745.4 million deal for SM-3 Block IIA interceptors, extending ballistic missile interceptor production through 2031

RTX won a U.S. Department of War deal worth up to $745.4 million for SM-3 Block IIA ballistic missile interceptors, extending production through 2031. The first tranche totals $275.6 million from the U.S. defense budget and $277.6 million from Japan’s MoD. SM-3 Block IIA uses a kinetic warhead and Mk 41 launchers. It saw documented combat use in April 2024 against Iranian missiles.